$0.00
(Market cap
$10 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
87.6 %
Quality Score
/10
Growth Score
/10
Valuation Score
/10
Momentum Score
/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-8.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.6
-
Face value
--
-
Shares outstanding
47,308,394
10 Years Aggregate
CFO
$-160.39 Mln
EBITDA
$-184.90 Mln
Net Profit
$-172.04 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
ESSA Pharma - ADR
| -88.8 | -15.2 | -88.2 | -96.5 | -50.5 | -49.9 | -47.5 |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
ESSA Pharma - ADR
| 161.9 | -82.3 | 19.0 | 116.9 | 161.9 | -51.9 | -90.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
ESSA Pharma - ADR
|
0.2 | 9.5 | 0.1 | -25.3 | -20,363.0 | -22.2 | -- | 0.1 |
| 11.4 | 3,668.2 | 66.2 | -164.7 | -304.6 | -17.7 | -- | 4.2 | |
| 16.3 | 2,215.3 | 311.5 | 314.1 | 54.2 | 52.5 | 7.3 | 3.7 | |
| 6.5 | 351.6 | 0.0 | -37.5 | 133,972.6 | -79.5 | -- | 9.2 | |
| 4.7 | 42.7 | 0.1 | -14.1 | -28,293.9 | -123.9 | -- | 114.5 | |
| 12.0 | 395.9 | 59.2 | -3.3 | -4.2 | -8.3 | -- | 9.4 | |
| 1.4 | 7.8 | 663.9 | -9.9 | -1.5 | -86 | -- | 1.2 | |
| 1.1 | 131.4 | 2.3 | -84.0 | -3,131.9 | -280.1 | -- | 7.2 | |
| 60.0 | 5,885.0 | 0.0 | -409.2 | -- | -44.9 | -- | 4.7 |
Shareholding Pattern
View DetailsAbout ESSA Pharma - ADR
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025,... ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc. Read more
-
President, CEO & Director
Dr. David Ross Parkinson M.D.
-
President, CEO & Director
Dr. David Ross Parkinson M.D.
-
Headquarters
Vancouver, BC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for ESSA Pharma - ADR
What is the current share price of ESSA Pharma Inc - ADR Today?
The share price of ESSA Pharma Inc - ADR is $0.20 (NASDAQ) as of 09-Oct-2025 09:30 EDT. ESSA Pharma Inc - ADR has given a return of -50.53% in the last 3 years.
What is the current PB & PE ratio of ESSA Pharma Inc - ADR?
Since, TTM earnings of ESSA Pharma Inc - ADR is negative, P/E ratio is not available.
The P/B ratio of ESSA Pharma Inc - ADR is 0.09 times as on 09-Oct-2025, a 98 discount to its peers’ median range of 4.66 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-9.42 |
2.16 |
2023 |
-5.13 |
0.94 |
2022 |
-2.29 |
0.48 |
2021 |
-8.92 |
1.69 |
2020 |
-8.04 |
2.38 |
What is the 52 Week High and Low of ESSA Pharma Inc - ADR?
The 52-week high and low of ESSA Pharma Inc - ADR are Rs 6.45 and Rs 0.18 as of 28-Aug-2026.
What is the market cap of ESSA Pharma Inc - ADR?
ESSA Pharma Inc - ADR has a market capitalisation of $ 10 Mln as on 09-Oct-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in ESSA Pharma Inc - ADR?
Before investing in ESSA Pharma Inc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.